PROMISE: Our kitties will never sit on top of content. Please turn off your ad blocker for our site.
puuuuuuurrrrrrrrrrrr
Michael Causey
Published: Tuesday, May 5, 2015 - 17:01 (AssurX: Morgan Hill, CA) -- A new FDA guidance issued by the Center for Devices and Radiological Health (CDRH) and Center for Biologics Evaluation and Research (CBER) offers some helpful detail for device firms uncertain if post-approval studies can replace premarket studies at the time of approval for premarket approval applications (PMAs). The agency says there are some instances where it may consider it acceptable to collect certain data in a postmarket setting rather than premarket. One area is mature technologies. For example, a subcutaneous implantable cardioverter defibrillator (S-ICD) has the same basic elements of an ICD, which have been used for decades. Clinical and preclinical evaluations in the premarket setting for the subcutaneous ICD were tailored to collect data on the new aspects and to evaluate functionality of the device, while more detailed safety data are collected in a postmarket study. Other situations include an urgent public health need, especially in a situation where postmarket testing would do a better job confirming the benefits of a device. The guidance spells out several other examples where it may be appropriate, including: First published April 20, 2015, on the AssurX blog. Quality Digest does not charge readers for its content. We believe that industry news is important for you to do your job, and Quality Digest supports businesses of all types. However, someone has to pay for this content. And that’s where advertising comes in. Most people consider ads a nuisance, but they do serve a useful function besides allowing media companies to stay afloat. They keep you aware of new products and services relevant to your industry. All ads in Quality Digest apply directly to products and services that most of our readers need. You won’t see automobile or health supplement ads. So please consider turning off your ad blocker for our site. Thanks, James Michael Causey’s been a journalist since he started his own neighborhood newspaper in the 1970s. In addition to quizzing FDA officials for the past 10+ years, he’s also interviewed political satirist Art Buchwald, FCC Chairman Reed Hundt, SEC Chairwoman Mary Schapiro, and is the past president of the Washington Independent Writers. Causey is the editor and publisher of eDataIntegrityReport.com and is a contributing writer on the AssurXblog.FDA Works to Clarify Device Data Collection Priorities
Some post-approval studies can replace premarket studies
• Migration, an approach used when approval of Class III in vitro diagnostic devices previously approved, licensed, or cleared assay is shifted to another system for which the FDA hasn’t evaluated assay performance, is suitable in cases when sufficient knowledge can be gleaned for the documentation of design controls, risk analyses, and prior performance studies on an already marketed system
• Confirmation of mitigation effectiveness for a known risk in a post-approval study
• Modifying warnings, contraindications, or precautions in approved labeling
• Approval for an intended population beyond what was fully evaluated in the pivotal trial, with a confirmatory post-approval study
• Assessment of long-term performance in a post-approval study
• Assessment of rare adverse events in a post-approval study
• Confirmation of bench data with clinical data collected in a post-approval study
• Where the performance of a particular device type is well-studied, documented, and understood
• Where long-term outside the U.S. clinical performance data are available but deemed insufficient
Our PROMISE: Quality Digest only displays static ads that never overlay or cover up content. They never get in your way. They are there for you to read, or not.
Quality Digest Discuss
About The Author
Michael Causey
© 2022 Quality Digest. Copyright on content held by Quality Digest or by individual authors. Contact Quality Digest for reprint information.
“Quality Digest" is a trademark owned by Quality Circle Institute, Inc.